argenx (NASDAQ:ARGX) PT Raised to €425.00 at Deutsche Bank Aktiengesellschaft

argenx (NASDAQ:ARGXGet Rating) had its price target upped by Deutsche Bank Aktiengesellschaft from €400.00 ($408.16) to €425.00 ($433.67) in a research note released on Thursday, The Fly reports. The firm currently has a buy rating on the stock.

Several other research analysts also recently commented on ARGX. JPMorgan Chase & Co. raised their target price on argenx from €390.00 ($397.96) to €430.00 ($438.78) and gave the stock an overweight rating in a research note on Thursday, July 14th. HC Wainwright raised their target price on argenx from $400.00 to $425.00 and gave the stock a buy rating in a research note on Friday, July 29th. Robert W. Baird restated a downgrade rating on shares of argenx in a research note on Friday, July 29th. SVB Leerink raised their target price on argenx from $404.00 to $428.00 and gave the stock an outperform rating in a research note on Friday, July 29th. Finally, JMP Securities reiterated a buy rating and set a $427.00 price target on shares of argenx in a research report on Thursday. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $399.65.

argenx Stock Performance

ARGX stock opened at $356.71 on Thursday. The company has a market capitalization of $19.64 billion, a price-to-earnings ratio of -20.58 and a beta of 0.83. argenx has a fifty-two week low of $249.50 and a fifty-two week high of $403.77. The stock has a fifty day moving average of $374.25 and a 200-day moving average of $340.23.

argenx (NASDAQ:ARGXGet Rating) last issued its earnings results on Thursday, July 28th. The company reported ($3.81) EPS for the quarter, topping the consensus estimate of ($4.76) by $0.95. argenx had a negative return on equity of 49.45% and a negative net margin of 538.17%. The business had revenue of $85.18 million during the quarter, compared to the consensus estimate of $40.05 million. Equities analysts predict that argenx will post -15.52 EPS for the current year.

Hedge Funds Weigh In On argenx

A number of large investors have recently modified their holdings of the company. Glassman Wealth Services raised its holdings in shares of argenx by 69.4% during the 2nd quarter. Glassman Wealth Services now owns 83 shares of the company’s stock valued at $31,000 after buying an additional 34 shares in the last quarter. Lindbrook Capital LLC increased its stake in argenx by 32.1% in the 2nd quarter. Lindbrook Capital LLC now owns 144 shares of the company’s stock worth $55,000 after purchasing an additional 35 shares during the period. Parallel Advisors LLC increased its stake in argenx by 13.9% in the 2nd quarter. Parallel Advisors LLC now owns 337 shares of the company’s stock worth $128,000 after purchasing an additional 41 shares during the period. Comerica Bank increased its stake in argenx by 5.0% in the 2nd quarter. Comerica Bank now owns 874 shares of the company’s stock worth $326,000 after purchasing an additional 42 shares during the period. Finally, KB Financial Partners LLC increased its stake in argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the period. 59.75% of the stock is owned by hedge funds and other institutional investors.

About argenx

(Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

Recommended Stories

The Fly logo

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.